Costs, innovation and efficiency in anti-infective therapy

PharmacoEconomics

Volumn 9, Issue SUPPL. 1, 1996, Pages 31-39

  Bootman, J Lyle ^a   Milne, Richard J ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 9544245934     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199600091-00007     Document Type: Review

References (43)

1. Hillman A. Cost effectiveness opportunities for new antibiotics. PharmacoEconomics 1994; 5 Suppl. 2: 40-3
2. Jones-Grizzle AJ, Bootman JL. Pharmacoeconomics of genetically engineered drugs. PharmacoEconomics 1992; 1 (1): 45-53
3. Amadio J, Mueller J, Casey R. Benefit/cost ratios in public health. Illinois Department of Public Health, Southern Illinois University, Carbondale and Jackson County Health Department, August 1976
4. Bootman JL, McGhan WF. A perspective on the cost-benefit of drug therapy. J Clin Res Pract Drug Reg Affairs 1985; 3: 53-69
5. Holliday SM, Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. PharmacoEconomics 1994; 5 (2): 147-71
6. Perez-Tirse J, Gross PA. Review of cost-benefit analysis of influenza vaccine. PharmacoEconomics 1992; 2 (3): 198-206
7. Conway SP, Lease B. Routine childhood immunisation: is it worth it? PharmacoEconomics 1992; 3 (3): 183-91
8. van den Oever R, de Graeve D, Hepp B, et al. Pharmacoeconomics of immunisation: a review. PharmacoEconomics 1993; 3 (4): 286-308
9. Clements DA. Cost of treatment and prevention of Type b disease: an international perspective. PharmacoEconomics 1994; 6 (5): 442-52
10. Vaccination coverage of 2-year-old children United States, 1993. MMWR- Morb Mortal Wkly Rep 1994 Oct 7; 43 (39): 705-9
11. Levy RA. Prescription cost sharing: economic and health impacts, and implications for health policy. PharmacoEconomics 1992; 2 (3): 219-37
12. American Council on Pharmaceutical Education. Proposed Revision of Accreditation Guidelines for the Doctor of Pharmacy Degree. Chicago, Illinois. April 1993
13. Barriere SL. The economic impact of HA-1A (Centoxin) against Endotoxin. PharmacoEconomics 1992; 2 (5): 408-13
14. Chalfin DB, Holbein BME, Fein AM, et al. Cost effectiveness of monoclonal antibodies to Gram-negative endotoxin in the treatment of Gram-negative sepsis in ICU patients. J Am Med Assoc 1993; 269 (2): 249-54
15. Luce JM. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med 1993; 21 (8): 1233-40
16. Schulman KA, Glick HA, Rubin H, et al. Cost effectiveness of HA-1A monoclonal antibody for Gram-negative sepsis. J Am Med Assoc 1991; 266: 3466-71
17. Scott WG, Tilyard MW, Dovey SM, et al. Roxithromycin versus cefaclor in lower respiratory tract infection. PharmacoEconomics 1993; 4 (2): 122-30
18. Persson U, Tennvall GR, Andersson S, et al. Cost effectiveness of treatment with liposomal amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. PharmacoEconomics 1992; 2 (6): 500-8
19. Lipsy RJ. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. PharmacoEconomics 1992; 4 (1): 265-81
20. Detsky A. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 1993; 3: 354-61
21. Henry D. Economic analysis as an aid to subsidisation: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992; 1: 54-67
22. Boston Consulting Group. The changing environment for US Pharmaceuticals. Boston, Massachusetts. April, 1993
23. Lewis NJW. Outcomes research: where does the FDA stand? PharmacoResources 1995; 22: 3
24. Di Masi JA. Rising research and development costs for new drugs in a cost containment environment. PharmacoEconomics 1992; 1 Suppl. 1: 13-20
25. de Lissovoy G, Elixhauser A, Luce B, et al. Cost analysis of imipenem versus clindamycin with tobramycin in the treatment of acute intraabdominal infection. PharmacoEconomics 1993; 4 (3): 203-14
26. Bozzette SA, Parker R, Hay J. A cost analysis of approved anti-retroviral strategies in persons with advanced virus disease and zidovudine intolerance. J Acq Immune Def Synd 1994; 7: 355-62
27. Balestra DJ, Littenberg B. Should tetanus immunization be given as a single vaccination at age 65. J Gen Int Med 1993; 8: 404-12
28. Gladen HE. Evaluating the cost effectiveness of treatment with 3rd generation cephalosporins. Diag Micro Infect Dis 1992; 15: 99-105
29. Mohle-Boetani JC, Schuchat A, Plikaytis BD. Comparison of prevention strategies for neonatal group B streptococcal infection. A population based economic analysis. J Am Med Ass 1993; 270: 1442-8
30. Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994; 28: 384-9
31. Schecter CB. Decision analysis in formulary decision making. PharmacoEconomics 1993; 3: 454-61
32. Szymusiak-Mutnick B, Mutnick AH. Application of decision analysis in antibiotic formulary choices. J Pharm Tech 1994; 10: 23-6
33. Bonertz L. Sparfloxacin: positive impact predicted. PharmacoResources 1994; 5 (16): 3
34. Bootman JL, Wertheimer AI, Zaske D, et al. Individualising gentamicin dosage regimens in burn patients with Gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979; 68: 267-72
35. Lewis NJW, Patwell JT, Briesacher BA. The role of insurance claims databases in drug therapy outcomes research. PharmacoEconomics 1993; 4 (5): 323-30
36. Eisenberg JA. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Int Med 1987; 107: 900-9
37. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Int Med 1989; 149: 1019-22
38. Balfour JA, Faulds D. Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infection. PharmacoEconomics 1993; 3 (5): 398-421
39. Grasela TH, Paladino JA, Schentag JJ, et al. Clinical and economic impact of oral ciprofloxacin as follow up to parenteral antibiotics. DICP, Annal Pharmacother 1991; 25: 857-62
40. Parker SE, Davey PG. Pharmacoeconomic evaluation of intravenous drug administration. PharmacoEconomics 1992; 1 (2): 103-15
41. Sullivan S, Kreling DH, Hazlet TR. Noncompliance with medication regimens and subsequent hospitalisations. J Res Pharmaceut Econom 1990; 2: 19-33
42. Editorial. The economics of noncompliance. PharmacoResources 1995; 22: 4
43. Johnson J, Bootman JL. Drug related morbidity/mortality and pharmaceutical care. Final report to the Coalition tor Consumer Access to Pharmaceutical Care. Washington DC. Arch Intern Med. In press